Freemont Management S.A. Makes New $13.76 Million Investment in IQVIA Holdings Inc. $IQV

Freemont Management S.A. bought a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 80,700 shares of the medical research company’s stock, valued at approximately $13,763,000. IQVIA accounts for 2.1% of Freemont Management S.A.’s holdings, making the stock its 9th biggest holding.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in IQV. Boston Partners purchased a new stake in shares of IQVIA in the 3rd quarter worth $676,698,000. Norges Bank bought a new stake in IQVIA during the fourth quarter valued at about $497,445,000. Victory Capital Management Inc. grew its holdings in IQVIA by 2,628.1% during the fourth quarter. Victory Capital Management Inc. now owns 1,675,479 shares of the medical research company’s stock valued at $377,670,000 after purchasing an additional 1,614,063 shares during the period. Orbis Allan Gray Ltd increased its position in IQVIA by 96.5% in the fourth quarter. Orbis Allan Gray Ltd now owns 1,901,091 shares of the medical research company’s stock worth $428,525,000 after buying an additional 933,554 shares in the last quarter. Finally, AQR Capital Management LLC raised its stake in shares of IQVIA by 130.2% in the second quarter. AQR Capital Management LLC now owns 1,555,298 shares of the medical research company’s stock worth $245,099,000 after buying an additional 879,701 shares during the period. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Stock Down 2.0%

NYSE IQV opened at $206.26 on Friday. The company has a debt-to-equity ratio of 2.20, a quick ratio of 0.75 and a current ratio of 0.75. The company has a market capitalization of $34.42 billion, a P/E ratio of 25.56, a P/E/G ratio of 1.85 and a beta of 1.20. IQVIA Holdings Inc. has a one year low of $154.50 and a one year high of $247.04. The stock has a 50 day moving average price of $185.04 and a 200-day moving average price of $188.16.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.83 by $0.07. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The company had revenue of $4.15 billion for the quarter, compared to the consensus estimate of $4.10 billion. During the same quarter in the prior year, the firm earned $2.70 earnings per share. IQVIA’s revenue was up 8.4% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. As a group, equities analysts predict that IQVIA Holdings Inc. will post 11.57 EPS for the current fiscal year.

IQVIA announced that its Board of Directors has authorized a stock buyback program on Thursday, May 7th that authorizes the company to buyback $2.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to purchase up to 6.8% of its shares through open market purchases. Shares buyback programs are typically a sign that the company’s board of directors believes its stock is undervalued.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on IQV shares. Morgan Stanley restated an “equal weight” rating and set a $200.00 target price (down from $225.00) on shares of IQVIA in a research note on Wednesday, June 17th. HSBC reissued a “buy” rating and issued a $240.00 price objective on shares of IQVIA in a research note on Monday, July 6th. Deutsche Bank Aktiengesellschaft set a $240.00 price objective on shares of IQVIA in a research report on Thursday, July 9th. Robert W. Baird upped their target price on shares of IQVIA from $230.00 to $249.00 and gave the stock an “outperform” rating in a report on Wednesday, July 1st. Finally, Wall Street Zen lowered IQVIA from a “buy” rating to a “hold” rating in a research note on Saturday, June 27th. Fourteen research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $225.71.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.